Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroki Kume

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Biochemical and Biophysical Research Communications|September 25, 2012
Acetoacetyl-CoA synthetase is essential for normal neuronal developmentShinya Hasegawa, Hiroki Kume, Sayuri Iinuma, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|October 10, 2024
Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)Hisato Kawakami, Koki Nakanishi, Akitaka Makiyama, et al.
Japanese Journal of Clinical Oncology|March 6, 2026
Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR studyYukiya Narita, Hisato Kawakami, Koki Nakanishi, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Biochemical and Biophysical Research Communications|September 25, 2012
Acetoacetyl-CoA synthetase is essential for normal neuronal developmentShinya Hasegawa, Hiroki Kume, Sayuri Iinuma, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|October 10, 2024
Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)Hisato Kawakami, Koki Nakanishi, Akitaka Makiyama, et al.
Japanese Journal of Clinical Oncology|March 6, 2026
Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR studyYukiya Narita, Hisato Kawakami, Koki Nakanishi, et al.
Pageof 1